1,332 reports of this reaction
2.2% of all BELIMUMAB reports
#10 most reported adverse reaction
ARTHRALGIA is the #10 most commonly reported adverse reaction for BELIMUMAB, manufactured by GlaxoSmithKline LLC. There are 1,332 FDA adverse event reports linking BELIMUMAB to ARTHRALGIA. This represents approximately 2.2% of all 60,128 adverse event reports for this drug.
Patients taking BELIMUMAB who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is a less commonly reported adverse event for BELIMUMAB, but still significant enough to appear in the safety profile.
In addition to arthralgia, the following adverse reactions have been reported for BELIMUMAB:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 1,332 FDA reports for BELIMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 2.2% of all adverse event reports for BELIMUMAB, making it a notable side effect.
If you experience arthralgia while taking BELIMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.